ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−3.58%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.67
From 52W high−88.27%
Volume417403.00
Market cap$39.76M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 29, 2026
Open
$0.67
From 52W high
−88.27%
Volume
417403.00
Market cap
$39.76M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
29.9
MomentumView details →
1D Return
−3.58%
YTD Return
−87.06%
SummaryUpdated Jun 1, 2026
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company founded in 2004 and based in Lexington, Massachusetts. Originally incorporated as Aldexa Therapeutics, the company changed its name to Aldeyra Therapeutics in March 2014, coinciding with its initial public offering. The company specializes in developing medicines for immune-mediated ocular and systemic diseases, with a focus on novel therapeutic approaches targeting reactive aldehyde species and other inflammatory pathways.
Similar companies
Latest newsMore news →
Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request with the FDA regarding its reproxalap program after an FDA rejection.30d agoAldeyra Therapeutics announced it will host a regulatory update webcast on September 29, 2026, focused on its investigational dry eye disease drug reproxalap.31d agoAldeyra Therapeutics, Inc. elected Todd C. Brady, M.D., Ph.D. as a Class III director and appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, effective June 9, 2026.142d ago